Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q92905
UPID:
CSN5_HUMAN
Alternative names:
Jun activation domain-binding protein 1
Alternative UPACC:
Q92905; O15386; Q6AW95; Q86WQ4; Q9BQ17
Background:
COP9 signalosome complex subunit 5, also known as Jun activation domain-binding protein 1, plays a pivotal role in cellular and developmental processes. It acts as a probable protease subunit within the COP9 signalosome complex, regulating the ubiquitin conjugation pathway through deneddylation of cullin subunits. This regulation decreases the ubiquitin ligase activity of SCF-type complexes, influencing various cellular pathways including phosphorylation of key proteins such as p53/TP53 and c-jun/JUN.
Therapeutic significance:
Understanding the role of COP9 signalosome complex subunit 5 could open doors to potential therapeutic strategies.